Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imaging of Patients With Malignant Brain Tumors Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers
NCT03465618Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2018
- Primary completion
- Mar 2027
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of zirconium Zr 89-DFO-cRGDY PEG-Cy5-C' dots in brain cancer and pituitary adenoma (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Distribution within high-grade gliomas at 2 years. Started Mar 2018; status: active, not recruiting.
02
Drugs
zirconium Zr 89-DFO-cRGDY PEG-Cy5-C' dots
03
Conditions
brain cancerpituitary adenoma
Beyond the preview
Go deeper on NCT03465618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03465618.